莫西沙星聯(lián)合頭孢菌素類抗菌藥物治療社區(qū)獲得性肺炎的療效評(píng)價(jià)

李征洋

【摘要】目的：討論社區(qū)獲得性肺炎以莫西沙星+頭孢菌素類抗菌藥物治療的效果。方法：選取2020年9月—2021年9月我院社區(qū)獲得性肺炎患者106例，隨機(jī)劃成：對(duì)照、觀察兩組（各53例）。對(duì)照組莫西沙星治療，觀察組在對(duì)照組基礎(chǔ)上增加頭孢匹胺，比較兩組的治療總有效率、康復(fù)時(shí)間、細(xì)菌清除率。結(jié)果：觀察組的治療總有效率高于對(duì)照組（P<0.05）；觀察組各癥狀康復(fù)時(shí)間短于對(duì)照組（P<0.05）；觀察組細(xì)菌清除率高于對(duì)照組（P<0.05）。結(jié)論：莫西沙星+頭孢匹胺的療效可觀，對(duì)社區(qū)獲得性肺炎的效果好，細(xì)菌清除率高，利于各項(xiàng)癥狀的快速消失，值得肯定。

【關(guān)鍵詞】莫西沙星；頭孢菌素類抗菌藥物；社區(qū)獲得性肺炎；細(xì)菌清除率

Efficacy Evaluation of Moxifloxacin Combined with Cephalosporin Antibiotics in the Treatment of Patients with Community-Acquired Pneumonia

LI Zhengyang

Horqin Right Front Banner Peoples Hospital， Hinggan League， Hinggan League， Inner Mongolia 137400， China

【Abstract】Objective：To discuss the effect of moxifloxacin+cephalosporin antibiotics in the treatment of community-acquired pneumonia. Methods：From September 2020 to September 2021，106 patients with community-acquired pneumonia in our hospital were randomly divided into two groups：control group and observationgroup（53cases in each group）.The control group was treated with moxifloxacin，and the observation group was increased with cefpiramide on the basis of the control group.The treatment total efficiency，recovery time，and bacterial clearance rate of the two groups were compared.Results：The total effective rate of treatment in the observation group was higher than that in the control group（P<0.05）；The recovery time of each symptomin the observation group was shorter than that in the control group（P<0.05）；The bacterial clearance rate in the observation group was higher than that in the control group （P<0.05）.Conclusion：Moxifloxacin+cefpiramide has considerable curative effect，good effect on community-acquired pneumonia，high bacterial clearance rate，and is conducive to the rapid disappearance of various symptoms，which is worthy of recognition.

【Key Words】Moxifloxacin； Cephalosporin antibiotics； Community-acquired pneumonia； Bacterial clearance rate

社區(qū)獲得性肺炎（Community Acquired Pneumonia，CAP）為醫(yī)院外感染的一種肺部炎癥，因感染病毒、細(xì)菌、衣原體、支原體等微生物所致[1]?；疾『?，患者會(huì)出現(xiàn)明顯的咳嗽、咳痰、胸疼等癥狀，與上呼吸道感染的癥狀有著一定相似之處，但該疾病的死亡率更高，對(duì)患者健康的威脅也更大。目前，我國的醫(yī)療技術(shù)不斷發(fā)展，治療CAP也有了新的成效，通過各種抗菌藥物的使用，各種致病菌均得到了有效清除[2]。不過，隨著治療時(shí)間的延長，患者對(duì)抗菌藥物也會(huì)產(chǎn)生相應(yīng)的耐藥性，而CAP的治療難度也會(huì)隨之提升，因此，還需選擇更為有效的治療方案，以便致病菌的有效清除。莫西沙星便為CAP治療中的常見藥，但對(duì)于患有基礎(chǔ)疾病的患者或老年人來說單一使用后的療效欠佳，需采用聯(lián)用的方案乃可實(shí)現(xiàn)治療效果的提升[3]。鑒于此，本文將把頭孢菌素類抗菌藥物與莫西沙星聯(lián)用，并分析其價(jià)值?，F(xiàn)論述如下。

1 資料與方法

1.1 一般資料

選取2020年9月—2021年9月我院CAP患者106例，隨機(jī)劃成：對(duì)照、觀察兩組。組間資料對(duì)比后（P>0.05），符合研究實(shí)施標(biāo)準(zhǔn)，具體數(shù)據(jù)信息，見表1。